Skip to main content

Advertisement

Table 1 Summary of articles and patient characteristics

From: Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

Study characteristics N = 8 DBPCTs; 915 patients
Publication year, range (2005 to 2013)
Multicenter vs. monocenter 4 (50%) vs. 4 (50%)
Allergen used (pollen vs. house dust mites) 6 (75%) vs. 2 (25%)
Treatment duration, range (months) (12 to 24)
Duration of symptoms and medication evaluation period, range (months) (1 to 12)
Total score in Jadad methodology scale, range (2 to 5)
Number of patients per study, range 45 to 269
Total number of patients in active group, n (%) 591 (64.6%)
Placebo group, n (%) 324 (35.4%)
Patient’ s age, mean (range), years 32 (7 to 69)
PDCO groups of age in included studies  
Children and adolescents included, n (%) 2 (25%)
Adolescents included, n (%) 4 (50%)
Only adults included, n (%) 2 (25%)
Rhinoconjunctivitis severity in included studies  
Any severity included, n (%) 4 (50%)
Only moderate to severe, n (%) 4 (50%)
Asthma severity in included studies  
Only include intermittent asthma, n (%) 3 (37.5%)
Intermittent to mild persistent included, n (%) 3 (37.5%)
Intermittent to moderate persistent included, n (%) 2 (25%)
% pts not included in per protocol set: active group (5% to 24%)
Placebo group (5% to 25%)
Studies with HRQL evaluated with RQLQ  
Yes* (692 patients) 4 (50%)
No** 4 (50%)
  1. HRQL health-related quality of life; n: number of patients, PDCO European Medicines Agency. Paediatric Committee, DBPCT double-blind placebo-controlled trial, QoL Quality of Life
  2. *Pfaar (2013)[11], Pfaar (2012)[10], Pfaar (2010)[9], Álvarez-Cuesta (2005)[15]
  3. **Höiby (2010)[12], García-Robaina (2006)[16], Ameal (2005)[14] and Colás (2006). It is interesting to note that the Höiby (2010) study evaluated health-related QoL with combined sum of scores of the pediatric RQLQ and RQLQ. This study was not evaluated in QoL analysis because they did not report RQLQ scores, separately